Bauer, Martin

[["dc.bibliographiccitation.firstpage","436"],["dc.bibliographiccitation.issue","4"],["dc.bibliographiccitation.journal","Central European Journal of Medicine"],["dc.bibliographiccitation.lastpage","442"],["dc.bibliographiccitation.volume","8"],["dc.contributor.author","Bergmann, Ingo"],["dc.contributor.author","Heetfeld, Maximilian"],["dc.contributor.author","Crozier, Thomas A."],["dc.contributor.author","Schafdecker, Hans G."],["dc.contributor.author","Poeschl, Rupert"],["dc.contributor.author","Wiese, Christoph Hermann"],["dc.contributor.author","Popov, Aron-Frederik"],["dc.contributor.author","Bauer, Martin"],["dc.contributor.author","Hinz, Jose Maria"],["dc.date.accessioned","2018-11-07T09:22:14Z"],["dc.date.available","2018-11-07T09:22:14Z"],["dc.date.issued","2013"],["dc.description.abstract","Outpatient surgery is increasingly being performed on patients with pre-existing cardiovascular and pulmonary disorders. These are relevant for anesthesia because of the inherent risk of hemodynamic instability. This study compared the hemodynamic course in ASA III patients undergoing knee arthroscopy with either peripheral block of the femoral and sciatic nerves or general anesthesia. We searched our patient database for ASA III patients who had undergone knee arthroscopy between 2005 and 2010. This is routinely performed in either regional or general anesthesia, and the patients were stratified according to the anesthetic. Hemodynamic parameters, process times, complications and postoperative pain documented in the charts were evaluated and compared. 130 ASA III outpatients underwent knee arthroscopy during the observation period. Regional anesthesia alone (n=65) was sufficient in 96%. Heart rate was more stable and blood pressure decreased less under regional than under general anesthesia (systolic pressure - 11 +/- 8% versus - 28 +/- 9%; p < 0.001). Patients with general anesthesia (n=65) required more circulatory support. Establishing the nerve block takes longer than inducing general anesthesia, but this was performed ahead of time and thus had no effect on work flow. The groups did not differ with regard to complication rates, and intensity of postoperative pain or satisfaction with the anesthetic. No patient showed evidence of nerve damage or neurological deficits. Peripheral nerve block provides a more stable hemodynamic course than general anesthesia in ASA III patients undergoing knee arthroscopy. (C) Versita Sp. z o.o."],["dc.identifier.doi","10.2478/s11536-012-0143-4"],["dc.identifier.isi","000320283200013"],["dc.identifier.uri","https://resolver.sub.uni-goettingen.de/purl?gro-2/29292"],["dc.notes.status","zu prüfen"],["dc.notes.submitter","Najko"],["dc.publisher","Versita"],["dc.relation.issn","1644-3640"],["dc.relation.issn","1895-1058"],["dc.title","Peripheral nerve blocks give greater hemodynamic stability than general anesthesia for ASA III patients undergoing outpatient knee arthroscopy"],["dc.type","journal_article"],["dc.type.internalPublication","yes"],["dc.type.peerReviewed","yes"],["dc.type.status","published"],["dspace.entity.type","Publication"]]

[["dc.bibliographiccitation.firstpage","233"],["dc.bibliographiccitation.issue","4"],["dc.bibliographiccitation.journal","The International Journal of Artificial Organs"],["dc.bibliographiccitation.lastpage","239"],["dc.bibliographiccitation.volume","36"],["dc.contributor.author","Hinz, Jose"],["dc.contributor.author","Molder, Jan Martin"],["dc.contributor.author","Hanekop, Gerd-Gunnar"],["dc.contributor.author","Weyland, Andreas"],["dc.contributor.author","Popov, Aron-Frederik"],["dc.contributor.author","Bauer, Martin"],["dc.contributor.author","Kazmaier, Stephan"],["dc.date.accessioned","2018-11-07T09:26:14Z"],["dc.date.available","2018-11-07T09:26:14Z"],["dc.date.issued","2013"],["dc.description.abstract","Purpose: The goal of this investigation was to examine the influence of two oxygenators with different membranes, made of either polypropylene (PPL) or polymethylpentane (PMP), on the plasma concentration of sevoflurane during cardiopulmonary bypass. Methods: The concentrations of sevoflurane during cardiopulmonary bypass were examined in patient plasma, endotracheal tubes, cardiotomy reservoirs and the outlets of the heart-lung oxygenators in twenty patients who underwent elective heart surgery. Results: The sevoflurane losses are smaller in cardiopulmonary bypass when using a polymethylpentane versus a polypropylene oxygenator. Ten minutes after beginning cardiopulmonary bypass, the sevoflurane plasma concentration in the PPL oxygenator group compared to the PMP oxygenator group fell significantly (PPL 0.48-1.79 (0.93) vs. PMP 0.80-2.15 (1.56) mu L x 100 mL(-1), p = 0.02). This difference persisted until ten minutes after the termination of cardiopulmonary bypass. Conclusion: The results of this study show that using a polymethylpentane membrane oxygenator rather than a polypropylene oxygenator significantly reduces the losses of sevoflurane, resulting in higher plasma concentrations and greater depth of anesthesia."],["dc.identifier.doi","10.5301/ijao.5000208"],["dc.identifier.isi","000320894500001"],["dc.identifier.pmid","23504814"],["dc.identifier.uri","https://resolver.sub.uni-goettingen.de/purl?gro-2/30252"],["dc.notes.status","zu prüfen"],["dc.notes.submitter","Najko"],["dc.publisher","Wichtig Editore"],["dc.relation.issn","0391-3988"],["dc.title","Reduced sevoflurane loss during cardiopulmonary bypass when using a polymethylpentane versus a polypropylene oxygenator"],["dc.type","journal_article"],["dc.type.internalPublication","yes"],["dc.type.peerReviewed","yes"],["dc.type.status","published"],["dspace.entity.type","Publication"]]

[["dc.bibliographiccitation.artnumber","e2035"],["dc.bibliographiccitation.issue","45"],["dc.bibliographiccitation.journal","Medicine"],["dc.bibliographiccitation.volume","94"],["dc.contributor.author","Mansur, Ashham"],["dc.contributor.author","Popov, Aron-Frederik"],["dc.contributor.author","Ameen, Abu Hanna"],["dc.contributor.author","Bergmann, Ingo"],["dc.contributor.author","Brandes, Ivo Florian"],["dc.contributor.author","Beißbarth, Tim"],["dc.contributor.author","Bauer, Martin"],["dc.contributor.author","Hinz, José Maria"],["dc.date.accessioned","2018-11-07T09:49:09Z"],["dc.date.available","2018-11-07T09:49:09Z"],["dc.date.issued","2015"],["dc.description.abstract","Hyperglycemia is common during and after Coronary Artery Bypass Graft Surgery (CABGS) and has been shown to be associated with poor clinical outcomes. In this study, we hypothesized that a moderate perioperative mean blood glucose level of<150mg/dL improves long-term survival in cardiac surgery patients. We conducted a prospective, observational cohort study in the heart center of the University Medical Center of Goettingen, Germany. Patients undergoing on-pump cardiac surgery were enrolled in this investigation. After evaluating perioperative blood glucose levels, patients were classified into 2 groups based on mean glucose levels: Glucose 150mg/dL and Glucose<150mg/dL. Patients were followed up for 5 years, and mortality within this period was recorded as the primary outcome parameter. Secondary outcome parameters included the length of ICU stay, the use of inotropic agents, the length of hospital stay, and the in-hospital mortality. A total of 455 consecutive patients who underwent cardiac surgery with cardiopulmonary bypass were enrolled in this investigation. A Kaplan-Meier survival analysis of the 5-year mortality risk revealed a higher mortality risk among patients with glucose levels 150mg/dL (P=0.0043, log-rank test). After adjustment for confounders in a multivariate Cox regression model, the association between glucose 150mg/dL and 5-year mortality remained significant (hazard ratio, 2.10; 95% CI, 1.30-3.39; P=0.0023). This association was corroborated by propensity score matching, in which Kaplan-Meier survival analysis demonstrated significant improvement in the 5-year survival of patients with glucose levels<150mg/dL (P=0.0339). Similarly, in-hospital mortality was significantly higher in patients with glucose 150mg/dL compared with patients with glucose<150mg/dL. Moreover, patients in the Glucose 150mg/dL group required significantly higher doses of the inotropic agent Dobutamine (mg/d) compared with patients in the Glucose<150mg/dL group (20.6 +/- 62.3 and 10.5 +/- 40.7, respectively; P=0.0104). Moreover, patients in the Glucose 150mg/dL group showed a significantly longer hospital stay compared with patients in the Glucose<150mg/dL group (28 +/- 23 and 24 +/- 19, respectively; P=0.0297). We conclude that perioperative blood glucose levels<150mg/dL are associated with improved 5-year survival in patients undergoing cardiac surgery. More studies are warranted to explain this effect."],["dc.description.sponsorship","Open-Access Publikationsfonds 2015"],["dc.identifier.doi","10.1097/MD.0000000000002035"],["dc.identifier.isi","000369537400066"],["dc.identifier.pmid","26559310"],["dc.identifier.purl","https://resolver.sub.uni-goettingen.de/purl?gs-1/12570"],["dc.identifier.uri","https://resolver.sub.uni-goettingen.de/purl?gro-2/35449"],["dc.notes.intern","Merged from goescholar"],["dc.notes.status","zu prüfen"],["dc.notes.submitter","Najko"],["dc.publisher","Lippincott Williams & Wilkins"],["dc.relation.issn","1536-5964"],["dc.relation.issn","0025-7974"],["dc.rights","CC BY-ND 4.0"],["dc.rights.uri","https://creativecommons.org/licenses/by-nd/4.0"],["dc.title","Perioperative Blood Glucose Levels < 150 mg/dL are Associated With Improved 5-Year Survival in Patients Undergoing On-Pump Cardiac Surgery A Prospective, Observational Cohort Study"],["dc.type","journal_article"],["dc.type.internalPublication","yes"],["dc.type.peerReviewed","yes"],["dc.type.status","published"],["dc.type.version","published_version"],["dspace.entity.type","Publication"]]

[["dc.bibliographiccitation.artnumber","128"],["dc.bibliographiccitation.journal","BMC Medicine"],["dc.bibliographiccitation.volume","13"],["dc.contributor.author","Mansur, Ashham"],["dc.contributor.author","Steinau, Maximilian"],["dc.contributor.author","Popov, Aron-Frederik"],["dc.contributor.author","Ghadimi, Michael B."],["dc.contributor.author","Beißbarth, Tim"],["dc.contributor.author","Bauer, Martin"],["dc.contributor.author","Hinz, José Maria"],["dc.date.accessioned","2018-11-07T09:56:35Z"],["dc.date.available","2018-11-07T09:56:35Z"],["dc.date.issued","2015"],["dc.description.abstract","Background: Previous investigations have presumed a potential therapeutic effect of statin therapy in patients with acute respiratory distress syndrome (ARDS). Statins are expected to attenuate inflammation in the lungs of patients with ARDS due to their anti-inflammatory effects. Clinical investigations of the role of statin therapy have revealed contradictory results. This study aimed to investigate whether pretreatment and continuous therapy with statins in patients with sepsis-associated ARDS are associated with 28-day survival according to disease severity (mild, moderate, or severe). Methods: Patients with sepsis-associated ARDS from the surgical intensive care were enrolled in this prospective observational investigation. ARDS was classified into three groups (mild, moderate, and severe); 28-day mortality was recorded as the primary outcome variable and organ failure was recorded as secondary outcome variable. Sequential Organ Failure Assessment scores and the requirements for organ support were evaluated throughout the observational period to assess organ failure. Results: 404 patients with sepsis-associated ARDS were enrolled in this investigation. The distribution of the ARDS subgroups was 13 %, 59 %, and 28 % for mild, moderate, and severe disease, respectively. Statin therapy improved 28-day survival exclusively in the patients with severe ARDS compared with patients without statin therapy (88.5 % and 62.5 %, respectively; P = 0.0193). To exclude the effects of several confounders, we performed multivariate Cox regression analysis, which showed that statin therapy remained a significant covariate for mortality (hazard ratio, 5.46; 95 % CI, 1.38-21.70; P = 0.0156). Moreover, after carrying a propensity score-matching in the severe ARDS cohort, Kaplan-Meier survival analysis confirmed the improved 28-day survival among patients with statin therapy (P = 0.0205). Patients with severe ARDS who received statin therapy had significantly more vasopressor-free days compared with those without statin therapy (13 +/- 7 and 9 +/- 7, respectively; P = 0.0034), and they also required less extracorporeal membrane oxygenation (ECMO) therapy and had more ECMO-free days (18 +/- 9 and 15 +/- 9, respectively; P = 0.0873). Conclusions: This investigation suggests a beneficial effect of continuous statin therapy in patients with severe sepsis-associated ARDS and a history of prior statin therapy. Further study is warranted to elucidate this potential effect."],["dc.description.sponsorship","Open-Access-Publikationsfonds 2015"],["dc.identifier.doi","10.1186/s12916-015-0368-6"],["dc.identifier.isi","000355790700001"],["dc.identifier.pmid","26033076"],["dc.identifier.purl","https://resolver.sub.uni-goettingen.de/purl?gs-1/13459"],["dc.identifier.uri","https://resolver.sub.uni-goettingen.de/purl?gro-2/36986"],["dc.notes.intern","Merged from goescholar"],["dc.notes.status","zu prüfen"],["dc.notes.submitter","Najko"],["dc.publisher","Biomed Central Ltd"],["dc.relation.issn","1741-7015"],["dc.rights","CC BY 4.0"],["dc.rights.uri","https://creativecommons.org/licenses/by/4.0"],["dc.title","Impact of statin therapy on mortality in patients with sepsis-associated acute respiratory distress syndrome (ARDS) depends on ARDS severity: a prospective observational cohort study"],["dc.type","journal_article"],["dc.type.internalPublication","yes"],["dc.type.peerReviewed","yes"],["dc.type.status","published"],["dc.type.version","published_version"],["dspace.entity.type","Publication"]]

[["dc.bibliographiccitation.firstpage","969"],["dc.bibliographiccitation.issue","11"],["dc.bibliographiccitation.journal","Artificial Organs"],["dc.bibliographiccitation.lastpage","979"],["dc.bibliographiccitation.volume","34"],["dc.contributor.author","Heidrich, Florian"],["dc.contributor.author","Sossalla, Samuel T."],["dc.contributor.author","Schotola, Hanna"],["dc.contributor.author","Vorkamp, Tobias"],["dc.contributor.author","Ortmann, Philipp"],["dc.contributor.author","Popov, Aron-Frederik"],["dc.contributor.author","Coskun, Kasim Oguz"],["dc.contributor.author","Rajab, Taufiek K."],["dc.contributor.author","Friedrich, Martin"],["dc.contributor.author","Sohns, Christian"],["dc.contributor.author","Hinz, Jose"],["dc.contributor.author","Bauer, Martin"],["dc.contributor.author","Quintel, Michael"],["dc.contributor.author","Schoendube, Friedrich Albert"],["dc.contributor.author","Schmitto, Jan Dieter"],["dc.date.accessioned","2018-11-07T08:37:19Z"],["dc.date.available","2018-11-07T08:37:19Z"],["dc.date.issued","2010"],["dc.description.abstract","We established a stable and reproducible animal model of chronic heart failure (CHF) in sheep to investigate biomolecular changes. Therefore, two biomarkers, adenosine monophosphate-activated protein kinase (AMPK) and vascular endothelial growth factor-A (VEGF-A) were examined to reveal their role during chronic ischemic conditions of the heart. AMPK was studied because it plays an important role in cellular energy homeostasis and its upregulation is associated with myocardial ischemia, whereas VEGF-A was studied because it acts as an important signaling protein for neoangiogenesis. We examined 15 juvenile sheep (mean weight, 78 +/- 4 kg; control, n = 3; ShamOP, n = 2; coronary microembolization [CME], n = 10). CHF was induced under fluoroscopic guidance by multiple sequential microembolizations (MEs) through bolus injection of polysterol microspheres (90 mu m, n = 25.000) into the left main coronary artery. CME was repeated up to three times at 2- to 3-week intervals until animals started to develop stable signs of CHF. All animals were followed for 3 months. Phosphorylation of AMPK, marking the activated protein form, was detected by Western blotting. VEGF-A and vascular endothelial growth factor-receptor 2 (VEGF-R2) mRNA were detected by real-time polymerase chain reaction. Glyceraldehyde-3-phosphate-dehydrogenase (GAPDH) was used as a reference housekeeping gene. All 10 CHF animals developed clinical signs of CHF as indicated by a significant decrease of cardiac output, decreased ejection fraction, as well as occurrence of tachycardia and tachypnoea. Western blots showed significant phosphorylation of AMPK in CME animals compared to the control group (phospho-adenosine monophosphate-activated protein kinase a) (GAPDH control: 0.0, CME left ventricle [LV]: 0.39 +/- 0.20, CME right ventricle [RV]: 0.53 +/- 0.30; P < 0.05). VEGF-A and VEGF-R2 expression in CME animal myocardium was within the range of the control group, but this data did not reach statistical significance due to the small size of this group. While microinjection was performed into the left main coronary artery, phosphorylation of AMPK and expression of VEGF-A and VEGF-R2 were significantly higher in the RV than in the LV. Multiple sequential intracoronary MEs can effectively induce myocardial dysfunction with clinical and biomolecular signs of chronic ischemic cardiomyopathy. Quantitative analysis of biomolecular markers showed a significantly higher phosphorylation of AMPK in CHF animals compared with control myocardium."],["dc.identifier.doi","10.1111/j.1525-1594.2010.01121.x"],["dc.identifier.isi","000284588300018"],["dc.identifier.pmid","21092039"],["dc.identifier.uri","https://resolver.sub.uni-goettingen.de/purl?gro-2/18501"],["dc.notes.status","zu prüfen"],["dc.notes.submitter","Najko"],["dc.publisher","Wiley-blackwell"],["dc.publisher.place","Hoboken"],["dc.relation.conference","6th International Conference on Pediatric Mechanical Circulatory Support Systems and Pediatric Cardiopulmonary Perfusion"],["dc.relation.eventlocation","Boston, MA"],["dc.relation.issn","1525-1594"],["dc.relation.issn","0160-564X"],["dc.title","The Role of Phospho-Adenosine Monophosphate-Activated Protein Kinase and Vascular Endothelial Growth Factor in a Model of Chronic Heart Failure"],["dc.type","conference_paper"],["dc.type.internalPublication","yes"],["dc.type.peerReviewed","yes"],["dc.type.status","published"],["dspace.entity.type","Publication"]]

[["dc.bibliographiccitation.artnumber","e0127761"],["dc.bibliographiccitation.issue","5"],["dc.bibliographiccitation.journal","PLoS ONE"],["dc.bibliographiccitation.volume","10"],["dc.contributor.author","Mansur, Ashham"],["dc.contributor.author","Liese, Benjamin"],["dc.contributor.author","Steinau, Maximilian"],["dc.contributor.author","Ghadimi, Michael B."],["dc.contributor.author","Bergmann, Ingo"],["dc.contributor.author","Tzvetkov, Mladen Vassilev"],["dc.contributor.author","Popov, Aron-Frederik"],["dc.contributor.author","Beißbarth, Tim"],["dc.contributor.author","Bauer, Martin"],["dc.contributor.author","Hinz, José Maria"],["dc.date.accessioned","2018-11-07T09:57:00Z"],["dc.date.available","2018-11-07T09:57:00Z"],["dc.date.issued","2015"],["dc.description.abstract","According to previous investigations, CD14 is suggested to play a pivotal role in initiating and perpetuating the pro-inflammatory response during sepsis. A functional polymorphism within the CD14 gene, rs2569190, has been shown to impact the pro-inflammatory response upon stimulation with lipopolysaccharide, a central mediator of inflammation in sepsis. In this study, we hypothesized that the strong pro-inflammatory response induced by the TT genotype of CD14 rs2569190 may have a beneficial effect on survival (30-day) in patients with sepsis. A total of 417 adult patients with sepsis (and of western European descent) were enrolled into this observational study. Blood samples were collected for rs2569190 genotyping. Patients were followed over the course of their stay in the ICU, and the 30-day mortality risk was recorded as the primary outcome parameter. Sepsis-related organ failure assessment (SOFA) scores were quantified at sepsis onset and throughout the observational period to monitor organ failure as a secondary variable. Moreover, organ support-free days were evaluated as a secondary outcome parameter. TT-homozygous patients were compared to C-allele carriers. Kaplan-Meier survival analysis revealed a higher 30-day mortality risk among C-allele carriers compared with T homozygotes (p = 0.0261). To exclude the effect of potential confounders (age, gender, BMI and type of infection) and covariates that varied at baseline with a p-value < 0.2 (e.g., comorbidities), we performed multivariate Cox regression analysis to examine the survival time. The CD14 rs2569190 C allele remained a significant covariate for the 30-day mortality risk in the multivariate analysis (hazard ratio, 2.11; 95% CI, 1.08-4.12; p = 0.0282). The 30-day mortality rate among C allele carriers was 23%, whereas the T homozygotes had a mortality rate of 13%. Additionally, an analysis of organ-specific SOFA scores revealed a significantly higher SOFA-Central nervous system score among patients carrying the C allele compared with T-homozygous patients (1.9 +/- 1.1 and 1.6 +/- 1.0, respectively; p = 0.0311). In conclusion, CD14 rs2569190 may act as a prognostic variable for the short-term outcome (30-day survival) in patients with sepsis."],["dc.description.sponsorship","Open Access Publikationsfonds 2015"],["dc.identifier.doi","10.1371/journal.pone.0127761"],["dc.identifier.isi","000355187300054"],["dc.identifier.pmid","26020644"],["dc.identifier.purl","https://resolver.sub.uni-goettingen.de/purl?gs-1/11869"],["dc.identifier.uri","https://resolver.sub.uni-goettingen.de/purl?gro-2/37077"],["dc.notes.intern","Merged from goescholar"],["dc.notes.status","zu prüfen"],["dc.notes.submitter","Najko"],["dc.publisher","Public Library Science"],["dc.relation.issn","1932-6203"],["dc.rights","CC BY 4.0"],["dc.rights.uri","https://creativecommons.org/licenses/by/4.0"],["dc.title","The CD14 rs2569190 TT Genotype Is Associated with an Improved 30-Day Survival in Patients with Sepsis: A Prospective Observational Cohort Study"],["dc.type","journal_article"],["dc.type.internalPublication","yes"],["dc.type.peerReviewed","yes"],["dc.type.status","published"],["dc.type.version","published_version"],["dspace.entity.type","Publication"]]

[["dc.bibliographiccitation.firstpage","198"],["dc.bibliographiccitation.issue","2"],["dc.bibliographiccitation.journal","European Journal of Cardio-Thoracic Surgery"],["dc.bibliographiccitation.lastpage","205"],["dc.bibliographiccitation.volume","46"],["dc.contributor.author","Schotola, Hanna"],["dc.contributor.author","Bräuer, Anselm"],["dc.contributor.author","Meyer, Katharina A. E."],["dc.contributor.author","Hinz, José"],["dc.contributor.author","Schöndube, Friedrich Albert"],["dc.contributor.author","Bauer, Martin"],["dc.contributor.author","Mohite, Prashant Nanasaheb"],["dc.contributor.author","Danner, Bernd Christoph"],["dc.contributor.author","Sossalla, Samuel Tobias"],["dc.contributor.author","Popov, Aron-Frederik"],["dc.date.accessioned","2018-11-07T09:36:49Z"],["dc.date.available","2018-11-07T09:36:49Z"],["dc.date.issued","2014"],["dc.description.abstract","Ticagrelor (BriliqueA (R)) is a novel reversible platelet inhibitor at P2Y12 receptor used in patients with acute coronary syndrome and patients undergoing percutaneous coronary interventions. Unlike clopidogrel (PlavixA (R)), ticagrelor has a quicker offset of action, and therefore, it seems that platelet function recovers faster on discontinuation of therapy. These drugs sometimes cannot be stopped before coronary artery bypass grafting due to the risk of stent thrombosis or in case of emergency operations. Therefore, we investigated whether the continued preoperative use of ticagrelor influences the perioperative course of cardiac surgical patients. The perioperative course and clinical outcomes of patients preoperatively receiving ticagrelor + acetylsalicylic acid (ASA) (n = 32) or clopidogrel + ASA (n = 49) until cardiac surgery, performed at University of Goettingen between January 2012 and December 2012, were studied. The study was designed as a retrospective observational study. The observation period started with the surgery and ended after 3 days. P < 0.05 was considered statistically significant. Preoperative data and intraoperative characteristics were almost similar among the groups. In the first 24 h, the median blood loss was 850 [780-1600] ml in the ticagrelor group and 680 [400-860] ml in the clopidogrel group (P = 0.0006). Furthermore, the median red blood cell transfusion (P = 0.0031), the median pooled platelet transfusion (P = 0.0012), the median prothrombin complex concentrate use (P = 0.0114) and the median fibrinogen use (P = 0.0118) were significantly higher in the ticagrelor group compared with the clopidogrel group. However, there was no statistical significance between the two groups regarding intensive care unit and hospital stay, mechanical ventilation time, incidence of acute kidney injury and mortality. Hence, a tendency towards more rethoracotomies due to bleeding in the ticagrelor group was observed (P = 0.0632). In cardiac surgical patients who are treated with ticagrelor + ASA until surgery, ticagrelor therapy is associated with a significantly higher blood loss, a significantly higher use of blood products and coagulation factors and higher incidence of rethoracotomies for bleeding compared with patients treated with clopidogrel + ASA."],["dc.identifier.doi","10.1093/ejcts/ezt571"],["dc.identifier.isi","000344968300011"],["dc.identifier.pmid","24420365"],["dc.identifier.uri","https://resolver.sub.uni-goettingen.de/purl?gro-2/32700"],["dc.notes.status","zu prüfen"],["dc.notes.submitter","Najko"],["dc.relation.issn","1873-734X"],["dc.relation.issn","1010-7940"],["dc.title","Perioperative outcomes of cardiac surgery patients with ongoing ticagrelor therapy: boon and bane of a new drug"],["dc.type","journal_article"],["dc.type.internalPublication","yes"],["dc.type.peerReviewed","yes"],["dspace.entity.type","Publication"]]

[["dc.bibliographiccitation.artnumber","e006616"],["dc.bibliographiccitation.issue","1"],["dc.bibliographiccitation.journal","BMJ Open"],["dc.bibliographiccitation.volume","5"],["dc.contributor.author","Mansur, Ashham"],["dc.contributor.author","Klee, Yvonne"],["dc.contributor.author","Popov, Aron-Frederik"],["dc.contributor.author","Erlenwein, Joachim"],["dc.contributor.author","Ghadimi, Michael B."],["dc.contributor.author","Beißbarth, Tim"],["dc.contributor.author","Bauer, Martin"],["dc.contributor.author","Hinz, José Maria"],["dc.date.accessioned","2018-11-07T10:03:51Z"],["dc.date.available","2018-11-07T10:03:51Z"],["dc.date.issued","2015"],["dc.description.abstract","Objective: To investigate whether common infection foci (pulmonary, intra-abdominal and primary bacteraemia) are associated with variations in mortality risk in patients with sepsis. Design: Prospective, observational cohort study. Setting: Three surgical intensive care units (ICUs) at a university medical centre. Participants: A total of 327 adult Caucasian patients with sepsis originating from pulmonary, intra-abdominal and primary bacteraemia participated in this study. Primary and secondary outcome measures: The patients were followed for 90 days and mortality risk was recorded as the primary outcome variable. To monitor organ failure, sepsis-related organ failure assessment (Sequential Organ Failure Assessment, SOFA) scores were evaluated at the onset of sepsis and throughout the observational period as secondary outcome variables. Results: A total of 327 critically ill patients with sepsis were enrolled in this study. Kaplan-Meier survival analysis showed that the 90-day mortality risk was significantly higher among patients with primary bacteraemia than among those with pulmonary and intra-abdominal foci (58%, 35% and 32%, respectively; p=0.0208). To exclude the effects of several baseline variables, we performed multivariate Cox regression analysis. Primary bacteraemia remained a significant covariate for mortality in the multivariate analysis (HR 2.10; 95% CI 1.14 to 3.86; p=0.0166). During their stay in the ICU, the patients with primary bacteraemia presented significantly higher SOFA scores than those of the patients with pulmonary and intra-abdominal infection foci (8.5 +/- 4.7, 7.3 +/- 3.4 and 5.8 +/- 3.5, respectively). Patients with primary bacteraemia presented higher SOFA-renal score compared with the patients with other infection foci (1.6 +/- 1.4, 0.8 +/- 1.1 and 0.7 +/- 1.0, respectively); the patients with primary bacteraemia required significantly more renal replacement therapy than the patients in the other groups (29%, 11% and 12%, respectively). Conclusions: These results indicate that patients with sepsis with primary bacteraemia present a higher mortality risk compared with patients with sepsis of pulmonary or intra-abdominal origins. These results should be assessed in patients with sepsis in larger, independent cohorts."],["dc.description.sponsorship","Open-Access-Publikationsfonds 2015"],["dc.identifier.doi","10.1136/bmjopen-2014-006616"],["dc.identifier.isi","000348171800032"],["dc.identifier.pmid","25564146"],["dc.identifier.purl","https://resolver.sub.uni-goettingen.de/purl?gs-1/11567"],["dc.identifier.uri","https://resolver.sub.uni-goettingen.de/purl?gro-2/38567"],["dc.notes.intern","Merged from goescholar"],["dc.notes.status","zu prüfen"],["dc.notes.submitter","Najko"],["dc.publisher","Bmj Publishing Group"],["dc.relation.issn","2044-6055"],["dc.rights","CC BY-NC 4.0"],["dc.rights.uri","https://creativecommons.org/licenses/by-nc/4.0"],["dc.title","Primary bacteraemia is associated with a higher mortality risk compared with pulmonary and intra-abdominal infections in patients with sepsis: a prospective observational cohort study"],["dc.type","journal_article"],["dc.type.internalPublication","yes"],["dc.type.peerReviewed","yes"],["dc.type.status","published"],["dc.type.version","published_version"],["dspace.entity.type","Publication"]]

[["dc.bibliographiccitation.artnumber","10539"],["dc.bibliographiccitation.journal","Scientific Reports"],["dc.bibliographiccitation.volume","5"],["dc.contributor.author","Mansur, Ashham"],["dc.contributor.author","Mulwande, Evelyn"],["dc.contributor.author","Steinau, Maximilian"],["dc.contributor.author","Bergmann, Ingo"],["dc.contributor.author","Popov, Aron-Frederik"],["dc.contributor.author","Ghadimi, Michael B."],["dc.contributor.author","Beißbarth, Tim"],["dc.contributor.author","Bauer, Martin"],["dc.contributor.author","Hinz, José Maria"],["dc.date.accessioned","2018-11-07T09:57:04Z"],["dc.date.available","2018-11-07T09:57:04Z"],["dc.date.issued","2015"],["dc.description.abstract","According to previous studies, the clinical course of sepsis could be affected by preexisting medical conditions, which are very common among patients with sepsis. This observational study aimed at investigating whether common chronic medical conditions affect the 90-day mortality risk in adult Caucasian patients with sepsis. A total of 482 patients with sepsis were enrolled in this study. The ninety-day mortality was the primary outcome; organ failure was the secondary outcome. Sepsis-related organ failure assessment (SOFA) scores and the requirements for organ support were evaluated to assess organ failure. A multivariate Cox regression model for the association between the 90-day mortality risk and chronic preexisting medical conditions adjusted for all relevant confounders and mortality predictors revealed the highest hazard ratio for patients with chronic kidney disease (CKD) (hazard ratio, 2.25; 95% CI, 1.46-3.46; p = 0.0002). Patients with CKD had higher SOFA scores than patients without CKD (8.9 perpendicular to 4.0 and 6.5 perpendicular to 3.4, respectively; p < 0.0001). Additionally, an analysis of organ-specific SOFA scores revealed higher scores in three organ systems (kidney, cardiovascular and coagulation). Patients with CKD have the highest 90-day mortality risk compared with patients without CKD or with other chronic medical conditions."],["dc.description.sponsorship","Open Access Publikationsfonds 2015"],["dc.identifier.doi","10.1038/srep10539"],["dc.identifier.isi","000355509300001"],["dc.identifier.pmid","25995131"],["dc.identifier.purl","https://resolver.sub.uni-goettingen.de/purl?gs-1/11870"],["dc.identifier.uri","https://resolver.sub.uni-goettingen.de/purl?gro-2/37088"],["dc.notes.intern","Merged from goescholar"],["dc.notes.status","zu prüfen"],["dc.notes.submitter","Najko"],["dc.publisher","Nature Publishing Group"],["dc.relation.issn","2045-2322"],["dc.rights","CC BY 4.0"],["dc.rights.uri","https://creativecommons.org/licenses/by/4.0"],["dc.title","Chronic kidney disease is associated with a higher 90-day mortality than other chronic medical conditions in patients with sepsis"],["dc.type","journal_article"],["dc.type.internalPublication","yes"],["dc.type.peerReviewed","yes"],["dc.type.status","published"],["dc.type.version","published_version"],["dspace.entity.type","Publication"]]

[["dc.bibliographiccitation.artnumber","R153"],["dc.bibliographiccitation.issue","4"],["dc.bibliographiccitation.journal","CRITICAL CARE"],["dc.bibliographiccitation.volume","16"],["dc.contributor.author","Schotola, Hanna"],["dc.contributor.author","Toischer, Karl"],["dc.contributor.author","Popov, Aron-Frederik"],["dc.contributor.author","Renner, Andre"],["dc.contributor.author","Schmitto, Jan Dieter"],["dc.contributor.author","Gummert, J. F."],["dc.contributor.author","Quintel, Michael"],["dc.contributor.author","Bauer, Martin"],["dc.contributor.author","Maier, Lars S."],["dc.contributor.author","Sossalla, Samuel Tobias"],["dc.date.accessioned","2018-11-07T09:14:39Z"],["dc.date.available","2018-11-07T09:14:39Z"],["dc.date.issued","2012"],["dc.description.abstract","Introduction: Pronounced extracellular acidosis reduces both cardiac contractility and the beta-adrenergic response. In the past, this was shown in some studies using animal models. However, few data exist regarding how the human end-stage failing myocardium, in which compensatory mechanisms are exhausted, reacts to acute mild metabolic acidosis. The aim of this study was to investigate the effect of mild metabolic acidosis on contractility and the beta-adrenergic response of isolated trabeculae from human end-stage failing hearts. Methods: Intact isometrically twitching trabeculae isolated from patients with end-stage heart failure were exposed to mild metabolic acidosis (pH 7.20). Trabeculae were stimulated at increasing frequencies and finally exposed to increasing concentrations of isoproterenol (0 to 1 x 10(-6) M). Results: A mild metabolic acidosis caused a depression in twitch-force amplitude of 26% (12.1 +/- 1.9 to 9.0 +/- 1.5 mN/mm(2); n = 12; P < 0.01) as compared with pH 7.40. Force-frequency relation measurements yielded no further significant differences of twitch force. At the maximal isoproterenol concentration, the force amplitude was comparable in each of the two groups (pH 7.40 versus pH 7.20). However, the half-maximal effective concentration (EC50) was significantly increased in the acidosis group, with an EC50 of 5.834 x 10(-8) M (confidence interval (CI), 3.48 x 10(-8) to 9.779 x 10(-8); n = 9), compared with the control group, which had an EC50 of 1.056 x 10(-8) M (CI, 2.626 x 10(-9) to 4.243 x 10(-8); n = 10; P < 0.05), indicating an impaired beta-adrenergic force response. Conclusions: Our data show that mild metabolic acidosis reduces cardiac contractility and significantly impairs the beta-adrenergic force response in human failing myocardium. Thus, our results could contribute to the still-controversial discussion about the therapy regimen of acidosis in patients with critical heart failure."],["dc.description.sponsorship","Open-Access-Publikationsfonds 2012"],["dc.identifier.doi","10.1186/cc11468"],["dc.identifier.isi","000313197800040"],["dc.identifier.pmid","22889236"],["dc.identifier.purl","https://resolver.sub.uni-goettingen.de/purl?gs-1/8331"],["dc.identifier.uri","https://resolver.sub.uni-goettingen.de/purl?gro-2/27466"],["dc.notes.intern","Merged from goescholar"],["dc.notes.status","zu prüfen"],["dc.notes.submitter","Najko"],["dc.publisher","Biomed Central Ltd"],["dc.relation.issn","1466-609X"],["dc.rights","CC BY 2.0"],["dc.rights.uri","https://creativecommons.org/licenses/by/2.0"],["dc.title","Mild metabolic acidosis impairs the beta-adrenergic response in isolated human failing myocardium"],["dc.type","journal_article"],["dc.type.internalPublication","yes"],["dc.type.peerReviewed","yes"],["dc.type.status","published"],["dc.type.version","published_version"],["dspace.entity.type","Publication"]]